Ofev treats adults with chronic fibrosing interstitial lung diseases with a progressive phenotype. It is the first treatment approved for this group of lung diseases.
The type of lung diseases Ofev can treat are caused by different underlying diseases or conditions and are characterized by lung scarring and rapid disease progression.
Progressive lung scarring leads to breathlessness and respiratory failure. Patients’ lung function declines over time, and the diseases can be debilitating and life-threatening.
Ofev was previously approved to treat other types of lung conditions, including idiopathic pulmonary fibrosis.
Read the full news release here.
More articles on pharmacy:
Coronavirus prompts fear of respiratory drug shortage
Bristol Myers Squibb reveals new branding after Celgene acquisition
Online pharmacy to offer 500 generic drugs for $5 monthly, delivery included
